Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory Routine −

VVT Med Provides Update on Management Cease Trade Order

Governance Risks Persist Despite Commercial Traction

By The Northwire Desk — AI Analysis May 15, 2026 · 17:31 VVTM · 0.21 VVT Med Inc.
Executive Summary
  • VVT Med Inc. provided an update on its Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission (BCSC).
  • The MCTO remains in effect due to continuous disclosure defaults regarding audited financial statements for fiscal year ended December 31, 2025.
  • The Company expects to complete filing of annual reports and Q1 2026 interim financials by June 29, 2026.
  • Trading restrictions prohibit the CEO and CFO from trading securities until filings are complete; public shareholders remain unaffected.
  • No material changes or new specified defaults have occurred since previous announcements as of May 15, 2026.
Material Impact
  • The update confirms the status quo established by the MCTO announcement on May 1, 2026, rather than introducing a new crisis.
  • While the commercial and clinical news (Italy distribution agreement, Indian clinical data) is positive, the regulatory default remains unresolved.
  • The inability of management to trade securities limits their ability to signal confidence or manage liquidity through insider transactions until June 29.
  • The delay in financial filings prevents full transparency on revenue recognition and cash burn for Q1 2026, creating information asymmetry for investors.
  • Given the market has already reacted to the initial MCTO announcement (price decline from $0.36 in late April to $0.21 by mid-May), this update is priced-in and does not materially shift the valuation thesis immediately.
VVTM · Price
Company Overview
  • VVT Med Inc. develops medical devices for vascular disease treatment.
  • Flagship Project: ScleroSafe catheter-directed sclerotherapy system for treating varicose veins (non-thermal, non-tumescent technology).
  • Regulatory Status: FDA-cleared and CE-marked; received CDSCO approval in India in 2022.
  • Commercial Milestones: Signed $3.7M distribution agreement in India (Nov 2025) and largest European agreement with Uber Ros S.p.A. for Italy/Vatican/San Marino ($2.3M potential, April 2026).
  • Clinical Data: Published peer-reviewed study showing 100% clinical success rate and high vein occlusion rates in India (April 2026).
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 12, 2026 · 17:00

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

Regulatory Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 26, 2026 · 08:00

Operational Milestone Achieved Amidst Regulatory Overhang

Production / Operations May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory